ASPM promotes prostate cancer stemness and progression by augmenting Wnt−Dvl-3−β-catenin signaling

Vincent C. Pai, Chung Chi Hsu, Tze Sian Chan, Wen Ying Liao, Chih Pin Chuu, Wei Yu Chen, Chi Rong Li, Ching Yu Lin, Shu Pin Hwang, Li Tzong Chen, Kelvin K. Tsai

研究成果: 雜誌貢獻文章

1 引文 (Scopus)

摘要

Recurrent and hormone-refractory prostate cancer (PCA) exhibits aggressive behaviors while current therapeutic approaches show little effect of prolonging the survival of patients with PCA. Thus, a deeper understanding of the patho-molecular mechanisms underlying the disease progression in PCA is crucial to identify novel diagnostic and/or therapeutic targets to improve the outcome of patients. Recent evidence suggests that activation of Wnt signaling in cancer stem cells (CSCs) contributes to cancer progression in malignant tumors. Here, we report that a novel Wnt co-activator ASPM (abnormal spindle-like microcephaly associated) maintains the prostate CSC subpopulation by augmenting the Wnt-β-catenin signaling in PCA. ASPM expression is incrementally upregulated in primary and metastatic PCA, implicating its potential role in PCA progression. Consistently, downregulation of ASPM expression pronouncedly attenuated the proliferation, colony formation, and the invasive behavior of PCA cells, and dramatically reduced the number of ALDH+ CSCs and inhibited cancer stemness and tumorigenicity. Mechanistically, ASPM interacts with disheveled-3 (Dvl-3), a cardinal upstream regulator of canonical Wnt signaling, and inhibits its proteasome-dependent degradation, thereby increasing its protein stability and enabling the Wnt-induced β-catenin transcriptional activity in PCA cells. In keeping with the role of ASPM as a CSC-regulator, ASPM co-localizes with ALDH in PCA tissues and its expression exhibits high intra-tumoral heterogeneity. The proportion of high-ASPM-expressing cells in the tumor inversely correlates with the relapse-free survival of PCA patients. Collectively, our data points to ASPM as a novel oncoprotein and an essential regulator of Wnt signaling and cancer stemness in PCA, which has important clinical and therapeutic significance.
原文英語
頁(從 - 到)1340-1353
期刊Oncogene
38
發行號8
DOIs
出版狀態已發佈 - 二月 21 2019

指紋

Catenins
Microcephaly
Prostatic Neoplasms
Neoplastic Stem Cells
Neoplasms
Survival
Protein Stability
Oncogene Proteins
Proteasome Endopeptidase Complex
Disease Progression
Therapeutics
Down-Regulation

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

引用此文

ASPM promotes prostate cancer stemness and progression by augmenting Wnt−Dvl-3−β-catenin signaling. / Pai, Vincent C.; Hsu, Chung Chi; Chan, Tze Sian; Liao, Wen Ying; Chuu, Chih Pin; Chen, Wei Yu; Li, Chi Rong; Lin, Ching Yu; Hwang, Shu Pin; Chen, Li Tzong; Tsai, Kelvin K.

於: Oncogene, 卷 38, 編號 8, 21.02.2019, p. 1340-1353.

研究成果: 雜誌貢獻文章

Pai, Vincent C. ; Hsu, Chung Chi ; Chan, Tze Sian ; Liao, Wen Ying ; Chuu, Chih Pin ; Chen, Wei Yu ; Li, Chi Rong ; Lin, Ching Yu ; Hwang, Shu Pin ; Chen, Li Tzong ; Tsai, Kelvin K. / ASPM promotes prostate cancer stemness and progression by augmenting Wnt−Dvl-3−β-catenin signaling. 於: Oncogene. 2019 ; 卷 38, 編號 8. 頁 1340-1353.
@article{58d236d5f87b4df296c398d9d041e499,
title = "ASPM promotes prostate cancer stemness and progression by augmenting Wnt−Dvl-3−β-catenin signaling",
abstract = "Recurrent and hormone-refractory prostate cancer (PCA) exhibits aggressive behaviors while current therapeutic approaches show little effect of prolonging the survival of patients with PCA. Thus, a deeper understanding of the patho-molecular mechanisms underlying the disease progression in PCA is crucial to identify novel diagnostic and/or therapeutic targets to improve the outcome of patients. Recent evidence suggests that activation of Wnt signaling in cancer stem cells (CSCs) contributes to cancer progression in malignant tumors. Here, we report that a novel Wnt co-activator ASPM (abnormal spindle-like microcephaly associated) maintains the prostate CSC subpopulation by augmenting the Wnt-β-catenin signaling in PCA. ASPM expression is incrementally upregulated in primary and metastatic PCA, implicating its potential role in PCA progression. Consistently, downregulation of ASPM expression pronouncedly attenuated the proliferation, colony formation, and the invasive behavior of PCA cells, and dramatically reduced the number of ALDH+ CSCs and inhibited cancer stemness and tumorigenicity. Mechanistically, ASPM interacts with disheveled-3 (Dvl-3), a cardinal upstream regulator of canonical Wnt signaling, and inhibits its proteasome-dependent degradation, thereby increasing its protein stability and enabling the Wnt-induced β-catenin transcriptional activity in PCA cells. In keeping with the role of ASPM as a CSC-regulator, ASPM co-localizes with ALDH in PCA tissues and its expression exhibits high intra-tumoral heterogeneity. The proportion of high-ASPM-expressing cells in the tumor inversely correlates with the relapse-free survival of PCA patients. Collectively, our data points to ASPM as a novel oncoprotein and an essential regulator of Wnt signaling and cancer stemness in PCA, which has important clinical and therapeutic significance.",
author = "Pai, {Vincent C.} and Hsu, {Chung Chi} and Chan, {Tze Sian} and Liao, {Wen Ying} and Chuu, {Chih Pin} and Chen, {Wei Yu} and Li, {Chi Rong} and Lin, {Ching Yu} and Hwang, {Shu Pin} and Chen, {Li Tzong} and Tsai, {Kelvin K.}",
year = "2019",
month = "2",
day = "21",
doi = "10.1038/s41388-018-0497-4",
language = "English",
volume = "38",
pages = "1340--1353",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - ASPM promotes prostate cancer stemness and progression by augmenting Wnt−Dvl-3−β-catenin signaling

AU - Pai, Vincent C.

AU - Hsu, Chung Chi

AU - Chan, Tze Sian

AU - Liao, Wen Ying

AU - Chuu, Chih Pin

AU - Chen, Wei Yu

AU - Li, Chi Rong

AU - Lin, Ching Yu

AU - Hwang, Shu Pin

AU - Chen, Li Tzong

AU - Tsai, Kelvin K.

PY - 2019/2/21

Y1 - 2019/2/21

N2 - Recurrent and hormone-refractory prostate cancer (PCA) exhibits aggressive behaviors while current therapeutic approaches show little effect of prolonging the survival of patients with PCA. Thus, a deeper understanding of the patho-molecular mechanisms underlying the disease progression in PCA is crucial to identify novel diagnostic and/or therapeutic targets to improve the outcome of patients. Recent evidence suggests that activation of Wnt signaling in cancer stem cells (CSCs) contributes to cancer progression in malignant tumors. Here, we report that a novel Wnt co-activator ASPM (abnormal spindle-like microcephaly associated) maintains the prostate CSC subpopulation by augmenting the Wnt-β-catenin signaling in PCA. ASPM expression is incrementally upregulated in primary and metastatic PCA, implicating its potential role in PCA progression. Consistently, downregulation of ASPM expression pronouncedly attenuated the proliferation, colony formation, and the invasive behavior of PCA cells, and dramatically reduced the number of ALDH+ CSCs and inhibited cancer stemness and tumorigenicity. Mechanistically, ASPM interacts with disheveled-3 (Dvl-3), a cardinal upstream regulator of canonical Wnt signaling, and inhibits its proteasome-dependent degradation, thereby increasing its protein stability and enabling the Wnt-induced β-catenin transcriptional activity in PCA cells. In keeping with the role of ASPM as a CSC-regulator, ASPM co-localizes with ALDH in PCA tissues and its expression exhibits high intra-tumoral heterogeneity. The proportion of high-ASPM-expressing cells in the tumor inversely correlates with the relapse-free survival of PCA patients. Collectively, our data points to ASPM as a novel oncoprotein and an essential regulator of Wnt signaling and cancer stemness in PCA, which has important clinical and therapeutic significance.

AB - Recurrent and hormone-refractory prostate cancer (PCA) exhibits aggressive behaviors while current therapeutic approaches show little effect of prolonging the survival of patients with PCA. Thus, a deeper understanding of the patho-molecular mechanisms underlying the disease progression in PCA is crucial to identify novel diagnostic and/or therapeutic targets to improve the outcome of patients. Recent evidence suggests that activation of Wnt signaling in cancer stem cells (CSCs) contributes to cancer progression in malignant tumors. Here, we report that a novel Wnt co-activator ASPM (abnormal spindle-like microcephaly associated) maintains the prostate CSC subpopulation by augmenting the Wnt-β-catenin signaling in PCA. ASPM expression is incrementally upregulated in primary and metastatic PCA, implicating its potential role in PCA progression. Consistently, downregulation of ASPM expression pronouncedly attenuated the proliferation, colony formation, and the invasive behavior of PCA cells, and dramatically reduced the number of ALDH+ CSCs and inhibited cancer stemness and tumorigenicity. Mechanistically, ASPM interacts with disheveled-3 (Dvl-3), a cardinal upstream regulator of canonical Wnt signaling, and inhibits its proteasome-dependent degradation, thereby increasing its protein stability and enabling the Wnt-induced β-catenin transcriptional activity in PCA cells. In keeping with the role of ASPM as a CSC-regulator, ASPM co-localizes with ALDH in PCA tissues and its expression exhibits high intra-tumoral heterogeneity. The proportion of high-ASPM-expressing cells in the tumor inversely correlates with the relapse-free survival of PCA patients. Collectively, our data points to ASPM as a novel oncoprotein and an essential regulator of Wnt signaling and cancer stemness in PCA, which has important clinical and therapeutic significance.

UR - http://www.scopus.com/inward/record.url?scp=85054385002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054385002&partnerID=8YFLogxK

U2 - 10.1038/s41388-018-0497-4

DO - 10.1038/s41388-018-0497-4

M3 - Article

VL - 38

SP - 1340

EP - 1353

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 8

ER -